IDT names William Conkling to board, taps him as audit committee chair
PUBT · 23h ago
Share
Listen to the news
- Irwin Katsof resigned from the board on June 9, 2026, stepping down from its committees.
- William Conkling was appointed to the board, with a term running to the 2026 annual meeting.
- Conkling is expected to chair the audit committee, serve as audit committee financial expert, join the compensation committee.
- Conkling has been chief commercial officer at Protara Therapeutics since June 2025.
- He previously led Rafael Holdings as CEO, held senior commercialization roles at Immunomedics, spent more than 10 years at Novartis.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDT Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-020335), on June 11, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved